Ureter and Renal Pelvis, Transitional Ce... Clinical Trials

• Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer
  ClinicalTrials.gov Identifier: NCT00005958 - Active, not recruiting
  stage III bladder cancer; regional transitional cell cancer of the renal pelvis and ureter; transitional cell carcinoma of the bladder; ...
  
• Trastuzumab in Treating Patients With Previously Treated, Locally Advanced or Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00004856 - Completed
  regional transitional cell cancer of the renal pelvis and ureter; recurrent transitional cell cancer of the renal pelvis and ureter; ...
  
• Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00003342 - Active, not recruiting
  stage III bladder cancer; stage IV bladder cancer; transitional cell carcinoma of the bladder; ...
  
• Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00003133 - Active, not recruiting
  stage III bladder cancer; stage IV bladder cancer; metastatic transitional cell cancer of the renal pelvis and ureter; ...
  
• Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
  ClinicalTrials.gov Identifier: NCT00066352 - Completed
  recurrent bladder cancer; stage IV bladder cancer; metastatic transitional cell cancer of the renal pelvis and ureter; ...
  
• R115777 in Treating Patients With Advanced Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00006376 - Active, not recruiting
  stage III bladder cancer; stage II bladder cancer; regional transitional cell cancer of the renal pelvis and ureter; ...
  
• Bortezomib in Treating Patients With Advanced Transitional Cell Carcinoma of the Urothelium
  ClinicalTrials.gov Identifier: NCT00072150 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00004223 - Active, not recruiting
  stage III bladder cancer; regional transitional cell cancer of the renal pelvis and ureter; transitional cell carcinoma of the bladder; ...
  
• Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
  ClinicalTrials.gov Identifier: NCT00066612 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00003520 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer; Renal Cell Adenocarcinoma; ...
  
• FR901228 in Treating Patients With Advanced Cancer of the Urothelium
  ClinicalTrials.gov Identifier: NCT00087295 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
  ClinicalTrials.gov Identifier: NCT00014274 - Recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
  ClinicalTrials.gov Identifier: NCT00112671 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter
  
• Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
  ClinicalTrials.gov Identifier: NCT00022633 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00003105 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter
  
• Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
  ClinicalTrials.gov Identifier: NCT00053209 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Pemetrexed Disodium in Treating Patients With Locally Advanced or Metastatic Recurrent Cancer of the Urothelium
  ClinicalTrials.gov Identifier: NCT00039260 - No longer recruiting
  recurrent bladder cancer; stage IV bladder cancer; transitional cell carcinoma of the bladder; ...
  
• Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract
  ClinicalTrials.gov Identifier: NCT00006111 - Active, not recruiting
  stage III bladder cancer; stage II bladder cancer; regional transitional cell cancer of the renal pelvis and ureter; anterior urethral cancer; ...
  
• Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
  ClinicalTrials.gov Identifier: NCT00005831 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00041106 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Combination Chemotherapy Followed By Observation or Surgery in Treating Patients With Stage II or Stage III Cancer of the Urothelium
  ClinicalTrials.gov Identifier: NCT00045630 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
  ClinicalTrials.gov Identifier: NCT00112905 - Recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
  ClinicalTrials.gov Identifier: NCT00022191 - Active, not recruiting
  stage IV bladder cancer; transitional cell carcinoma of the bladder; urethral cancer associated with invasive bladder cancer; ...
  
• ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
  ClinicalTrials.gov Identifier: NCT00014144 - Active, not recruiting
  recurrent urethral cancer; transitional cell carcinoma of the bladder; recurrent bladder cancer; stage IV bladder cancer; ...
  
• Short-Term Low-Dose Interferon alfa in Treating Patients With Cancer of the Urothelium
  ClinicalTrials.gov Identifier: NCT00082719 - Recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
  ClinicalTrials.gov Identifier: NCT00006351 - Active, not recruiting
  recurrent bladder cancer; stage IV bladder cancer; transitional cell carcinoma of the bladder; recurrent urethral cancer; anterior urethral cancer; ...
  
• Oxaliplatin in Treating Patients With Metastatic Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00004203 - Active, not recruiting
  transitional cell carcinoma of the bladder; recurrent bladder cancer; stage IV bladder cancer; ...
  
• Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
  ClinicalTrials.gov Identifier: NCT00003376 - Active, not recruiting
  stage III bladder cancer; stage IV bladder cancer; urethral cancer associated with invasive bladder cancer; ...
  
• Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00003175 - Active, not recruiting
  recurrent transitional cell cancer of the renal pelvis and ureter; recurrent urethral cancer; childhood kidney/urinary cancer; ...
  
• Docetaxel With or Without Vandetanib in Treating Patients With Previously Treated Stage IV Transitional Cell Cancer
  ClinicalTrials.gov Identifier: NCT00378794 - Recruiting
  Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter
  
• Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
  ClinicalTrials.gov Identifier: NCT00397488 - Recruiting
  Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
  
• Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
  ClinicalTrials.gov Identifier: NCT00021099 - Completed
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer
  ClinicalTrials.gov Identifier: NCT00028860 - Completed
  stage III bladder cancer; stage IV bladder cancer; transitional cell carcinoma of the bladder; ...
  
• Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium
  ClinicalTrials.gov Identifier: NCT00310011 - Active, not recruiting
  Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter
  
• Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
  ClinicalTrials.gov Identifier: NCT00363883 - Recruiting
  Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
  
• E7389 in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
  ClinicalTrials.gov Identifier: NCT00365157 - Recruiting
  Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
  
• VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
  ClinicalTrials.gov Identifier: NCT00407485 - Recruiting
  Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
  
• Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract
  ClinicalTrials.gov Identifier: NCT00002914 - Active, not recruiting
  recurrent urethral cancer; transitional cell carcinoma of the bladder; recurrent bladder cancer; ...
  
• Pazopanib in Treating Patients With Metastatic Urothelial Cancer
  ClinicalTrials.gov Identifier: NCT00471536 - Not yet recruiting
  Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
  
• Arsenic Trioxide in Treating Patients With Recurrent Bladder or Urinary Tract Cancer
  ClinicalTrials.gov Identifier: NCT00009867 - Active, not recruiting
  recurrent urethral cancer; transitional cell carcinoma of the bladder; recurrent bladder cancer; ...
  
• Gemcitabine, Paclitaxel, Doxorubicin, and Pegfilgrastim in Treating Patients With Metastatic or Unresectable Bladder Cancer or Urinary Tract Cancer and Kidney Dysfunction
  ClinicalTrials.gov Identifier: NCT00478361 - Recruiting
  Bladder Cancer; Neutropenia; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
  
• Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function
  ClinicalTrials.gov Identifier: NCT00005644 - Active, not recruiting
  Bladder Cancer; Cancer of the Renal Pelvis and Ureter; Gastrointestinal Cancer; Urethral Cancer
  
• Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
  ClinicalTrials.gov Identifier: NCT00080795 - Completed
  stage III bladder cancer; regional transitional cell cancer of the renal pelvis and ureter; anterior urethral cancer; posterior urethral cancer; ...
  
• Relationship of Ochratoxin A to Upper Urologic Cancers
  ClinicalTrials.gov Identifier: NCT00216801 - Recruiting
  Upper Tract Transitional Cell(TCC),; Renal Cell Cancer; Testicular Cancer
  
• Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma (Kidney Cancer)
  ClinicalTrials.gov Identifier: NCT00068393 - Active, not recruiting
  stage III renal cell cancer; Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
  ClinicalTrials.gov Identifier: NCT00060307 - Active, not recruiting
  recurrent renal cell cancer; Stage IV Renal Cell Cancer; stage III renal cell cancer
  
• ABT-510 in Treating Patients With Locally Recurrent or Metastatic Renal Cell (Kidney) Cancer
  ClinicalTrials.gov Identifier: NCT00080704 - Active, not recruiting
  recurrent renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer
  
• Sorafenib and Interferon alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00098618 - Active, not recruiting
  recurrent renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma; renal granular cell carcinoma
  
• Vaccine Therapy in Treating Patients With Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00096629 - Active, not recruiting
  recurrent renal cell cancer; stage I renal cell cancer; stage II renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer
  
• Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
  ClinicalTrials.gov Identifier: NCT00101608 - Completed
  Transitional Cell Carcinoma; Bladder Neoplasms; Kidney Neoplasms; Ureter Neoplasms
  
• Shark Cartilage Extract in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00005995 - Active, not recruiting
  Stage IV Renal Cell Cancer; Renal Cell Adenocarcinoma; recurrent renal cell cancer
  
• Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
  ClinicalTrials.gov Identifier: NCT00077129 - Active, not recruiting
  stage III renal cell cancer; Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00089102 - Active, not recruiting
  recurrent renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer
  
• Vaccine Therapy in Treating Patients With Transitional Cell Cancer of the Bladder
  ClinicalTrials.gov Identifier: NCT00070070 - Active, not recruiting
  transitional cell carcinoma of the bladder; stage I bladder cancer
  
• Chemotherapy in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00024388 - Active, not recruiting
  stage III renal cell cancer; Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00032188 - Active, not recruiting
  stage III renal cell cancer; Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00030888 - Active, not recruiting
  stage III renal cell cancer; Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00126659 - Active, not recruiting
  renal clear cell carcinoma; recurrent renal cell cancer; Stage IV Renal Cell Cancer
  
• Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically
  ClinicalTrials.gov Identifier: NCT00003664 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer; Quality of Life
  
• Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00087022 - Recruiting
  renal clear cell carcinoma; stage I renal cell cancer; stage II renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer
  
• Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00003585 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Vaccine Therapy in Treating Patients With Advanced Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00004880 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• BAY 59-8862 in Treating Patients With Advanced Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00039169 - Active, not recruiting
  stage III renal cell cancer; Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Interferon alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00002737 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer; Renal Cell Adenocarcinoma
  
• High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2
  ClinicalTrials.gov Identifier: NCT00080977 - Active, not recruiting
  recurrent renal cell cancer; Stage IV Renal Cell Cancer
  
• Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00006864 - Active, not recruiting
  Stage IV Renal Cell Cancer; renal clear cell carcinoma; recurrent renal cell cancer
  
• Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer
  ClinicalTrials.gov Identifier: NCT00083109 - Active, not recruiting
  recurrent renal cell cancer; Stage IV Renal Cell Cancer
  
• Interferon alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
  ClinicalTrials.gov Identifier: NCT00072046 - Active, not recruiting
  Stage IV Renal Cell Cancer; renal clear cell carcinoma; recurrent renal cell cancer
  
• Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00004890 - Active, not recruiting
  stage III renal cell cancer; Stage IV Renal Cell Cancer; drug extravasation; recurrent renal cell cancer; stage I renal cell cancer; ...
  
• Lymphocyte Therapy in Treating Patients With Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00002589 - Active, not recruiting
  stage III renal cell cancer; Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00025519 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer; renal clear cell carcinoma
  
• Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00003181 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• PS-341 in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00025376 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
  ClinicalTrials.gov Identifier: NCT00058318 - Active, not recruiting
  Stage IV Renal Cell Cancer; stage III renal cell cancer
  
• Tretinoin and Interleukin-2 in Treating Patients With Stage IV Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00100906 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer; renal clear cell carcinoma
  
• Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00039429 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Oblimersen and Interferon alfa in Treating Patients With Metastatic Renal Cell Cancer
  ClinicalTrials.gov Identifier: NCT00059813 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00003102 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Volociximab in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00103077 - Recruiting
  recurrent renal cell cancer; renal clear cell carcinoma; Stage IV Renal Cell Cancer
  
• Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00042965 - Active, not recruiting
  recurrent renal cell cancer; Stage IV Renal Cell Cancer
  
• Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00003928 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Sorafenib, Gemcitabine, and Capecitabine in Treating Patients with Unresectable and/Or Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00121251 - Recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer; stage III renal cell cancer
  
• AZD2171 in Treating Patients With Progressive Locally Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00227760 - Active, not recruiting
  Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer
  
• CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00112840 - Recruiting
  recurrent renal cell cancer; renal clear cell carcinoma; Stage IV Renal Cell Cancer
  
• Magnetic-Resonance-Guided Radiofrequency Ablation in Treating Patients With Primary Kidney Cancer, Liver Metastases, or Other Solid Tumors
  ClinicalTrials.gov Identifier: NCT00006255 - Active, not recruiting
  stage III renal cell cancer; Stage IV Renal Cell Cancer; recurrent renal cell cancer; unspecified adult solid tumor, protocol specific; ...
  
• Vaccine Therapy Combined With Interleukin-2 and Interferon alfa in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer)
  ClinicalTrials.gov Identifier: NCT00085436 - Active, not recruiting
  recurrent renal cell cancer; Stage IV Renal Cell Cancer
  
• Dolastatin 10 in Treating Patients With Advanced Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00003914 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• FR901228 in Treating Patients With Metastatic Renal Cell Cancer
  ClinicalTrials.gov Identifier: NCT00060216 - Recruiting
  recurrent renal cell cancer; Stage IV Renal Cell Cancer
  
• Tretinoin Plus Interferon alfa in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00003656 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00002846 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00003584 - Active, not recruiting
  Stage IV Renal Cell Cancer; childhood kidney/urinary cancer; recurrent renal cell cancer
  
• Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00005038 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00091403 - Active, not recruiting
  stage III renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma
  
• Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
  ClinicalTrials.gov Identifier: NCT00073879 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Vaccine Therapy in Treating Patients With Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00014131 - Recruiting
  stage III renal cell cancer; Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00093522 - Active, not recruiting
  recurrent renal cell cancer; Stage IV Renal Cell Cancer
  
• Sorafenib and Bevacizumab in Treating Patients With Advanced Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00126503 - Recruiting
  renal clear cell carcinoma; recurrent renal cell cancer; Stage IV Renal Cell Cancer
  
• Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00016042 - Active, not recruiting
  recurrent colon cancer; Stage IV Renal Cell Cancer; Stage IV rectal cancer; recurrent rectal cancer; recurrent renal cell cancer; ...
  
• Capecitabine Plus GTI-2040 in Treating Patients With Advanced or Metastatic Renal Cell Cancer
  ClinicalTrials.gov Identifier: NCT00084331 - Recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00005816 - Active, not recruiting
  stage III renal cell cancer; Stage IV Renal Cell Cancer